Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients

beta 2 glycoprotein I ( beta 2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti- beta 2GPI antibodies occur in normal individuals and transiently during the course of in...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2014-10, Vol.23 (12), p.1249-1251
Main Authors: Ribeiro, SLE, Pereira, HLA, Silva, N P, Sato, E I, Passos, LFS, Dos-Santos, M C
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1251
container_issue 12
container_start_page 1249
container_title Lupus
container_volume 23
creator Ribeiro, SLE
Pereira, HLA
Silva, N P
Sato, E I
Passos, LFS
Dos-Santos, M C
description beta 2 glycoprotein I ( beta 2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti- beta 2GPI antibodies occur in normal individuals and transiently during the course of infections, but are also associated with thrombotic events in autoimmune disease: the antiphospholipid syndrome (APS). A total of 31 out of 37 treated leprosy patients previously found to present high titers of IgM anti- beta 2GPI and/or anticardiolipin antibodies (aCL) remained positive for IgM antiphospholipid antibodies (aPL), and exhibited high titers of anti- beta 2GPI. The 37 patients were part of the 77 aPL-positive patients from a previous study that evaluated 158 leprosy patients. The median time elapsed between the first and second sample was 66 months. None of the 37 patients had any thrombotic event and 24 had a reactional state and were still requiring the use of prednisone, thalidomide or both. None of them fulfilled World Health Organization criteria for leprosy recurrence.
doi_str_mv 10.1177/0961203314529469
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1683348715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1683348715</sourcerecordid><originalsourceid>FETCH-LOGICAL-p118t-5be9f7a0471e6c28af1767fa5eadbdecb24b2c6ddb047f10b69663777f6dee393</originalsourceid><addsrcrecordid>eNotjTtPwzAUhT2ARCnsjB5ZDL52YscjqnhUigQDzJUf11WQ64TYHfrvSQXLOdKnT-cQcgf8AUDrR24UCC4lNK0wjTIXZHVG7MyuyHUp35xzCUatyEc_5j2rOB_ohHMZSsXskY6R2lwHRh1WSwXdp5Mfp3msOGS6pUvUGW3FQBMuuJzoZOuAuZYbchltKnj732vy9fL8uXlj_fvrdvPUswmgq6x1aKK2vNGAyovORtBKR9uiDS6gd6JxwqsQ3KJE4E4ZpaTWOqqAKI1ck_u_3eX-54il7g5D8ZiSzTgeyw5UJ2XTaWjlLyP3UeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1683348715</pqid></control><display><type>article</type><title>Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Ribeiro, SLE ; Pereira, HLA ; Silva, N P ; Sato, E I ; Passos, LFS ; Dos-Santos, M C</creator><creatorcontrib>Ribeiro, SLE ; Pereira, HLA ; Silva, N P ; Sato, E I ; Passos, LFS ; Dos-Santos, M C</creatorcontrib><description>beta 2 glycoprotein I ( beta 2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti- beta 2GPI antibodies occur in normal individuals and transiently during the course of infections, but are also associated with thrombotic events in autoimmune disease: the antiphospholipid syndrome (APS). A total of 31 out of 37 treated leprosy patients previously found to present high titers of IgM anti- beta 2GPI and/or anticardiolipin antibodies (aCL) remained positive for IgM antiphospholipid antibodies (aPL), and exhibited high titers of anti- beta 2GPI. The 37 patients were part of the 77 aPL-positive patients from a previous study that evaluated 158 leprosy patients. The median time elapsed between the first and second sample was 66 months. None of the 37 patients had any thrombotic event and 24 had a reactional state and were still requiring the use of prednisone, thalidomide or both. None of them fulfilled World Health Organization criteria for leprosy recurrence.</description><identifier>ISSN: 0961-2033</identifier><identifier>DOI: 10.1177/0961203314529469</identifier><language>eng</language><ispartof>Lupus, 2014-10, Vol.23 (12), p.1249-1251</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Ribeiro, SLE</creatorcontrib><creatorcontrib>Pereira, HLA</creatorcontrib><creatorcontrib>Silva, N P</creatorcontrib><creatorcontrib>Sato, E I</creatorcontrib><creatorcontrib>Passos, LFS</creatorcontrib><creatorcontrib>Dos-Santos, M C</creatorcontrib><title>Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients</title><title>Lupus</title><description>beta 2 glycoprotein I ( beta 2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti- beta 2GPI antibodies occur in normal individuals and transiently during the course of infections, but are also associated with thrombotic events in autoimmune disease: the antiphospholipid syndrome (APS). A total of 31 out of 37 treated leprosy patients previously found to present high titers of IgM anti- beta 2GPI and/or anticardiolipin antibodies (aCL) remained positive for IgM antiphospholipid antibodies (aPL), and exhibited high titers of anti- beta 2GPI. The 37 patients were part of the 77 aPL-positive patients from a previous study that evaluated 158 leprosy patients. The median time elapsed between the first and second sample was 66 months. None of the 37 patients had any thrombotic event and 24 had a reactional state and were still requiring the use of prednisone, thalidomide or both. None of them fulfilled World Health Organization criteria for leprosy recurrence.</description><issn>0961-2033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNotjTtPwzAUhT2ARCnsjB5ZDL52YscjqnhUigQDzJUf11WQ64TYHfrvSQXLOdKnT-cQcgf8AUDrR24UCC4lNK0wjTIXZHVG7MyuyHUp35xzCUatyEc_5j2rOB_ohHMZSsXskY6R2lwHRh1WSwXdp5Mfp3msOGS6pUvUGW3FQBMuuJzoZOuAuZYbchltKnj732vy9fL8uXlj_fvrdvPUswmgq6x1aKK2vNGAyovORtBKR9uiDS6gd6JxwqsQ3KJE4E4ZpaTWOqqAKI1ck_u_3eX-54il7g5D8ZiSzTgeyw5UJ2XTaWjlLyP3UeQ</recordid><startdate>20141001</startdate><enddate>20141001</enddate><creator>Ribeiro, SLE</creator><creator>Pereira, HLA</creator><creator>Silva, N P</creator><creator>Sato, E I</creator><creator>Passos, LFS</creator><creator>Dos-Santos, M C</creator><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>20141001</creationdate><title>Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients</title><author>Ribeiro, SLE ; Pereira, HLA ; Silva, N P ; Sato, E I ; Passos, LFS ; Dos-Santos, M C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p118t-5be9f7a0471e6c28af1767fa5eadbdecb24b2c6ddb047f10b69663777f6dee393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ribeiro, SLE</creatorcontrib><creatorcontrib>Pereira, HLA</creatorcontrib><creatorcontrib>Silva, N P</creatorcontrib><creatorcontrib>Sato, E I</creatorcontrib><creatorcontrib>Passos, LFS</creatorcontrib><creatorcontrib>Dos-Santos, M C</creatorcontrib><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ribeiro, SLE</au><au>Pereira, HLA</au><au>Silva, N P</au><au>Sato, E I</au><au>Passos, LFS</au><au>Dos-Santos, M C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients</atitle><jtitle>Lupus</jtitle><date>2014-10-01</date><risdate>2014</risdate><volume>23</volume><issue>12</issue><spage>1249</spage><epage>1251</epage><pages>1249-1251</pages><issn>0961-2033</issn><abstract>beta 2 glycoprotein I ( beta 2GPI) is a phospholipid binding protein that plays an important role in endothelial stability, blood coagulation, clearance of apoptotic debris and other physiologic processes. Anti- beta 2GPI antibodies occur in normal individuals and transiently during the course of infections, but are also associated with thrombotic events in autoimmune disease: the antiphospholipid syndrome (APS). A total of 31 out of 37 treated leprosy patients previously found to present high titers of IgM anti- beta 2GPI and/or anticardiolipin antibodies (aCL) remained positive for IgM antiphospholipid antibodies (aPL), and exhibited high titers of anti- beta 2GPI. The 37 patients were part of the 77 aPL-positive patients from a previous study that evaluated 158 leprosy patients. The median time elapsed between the first and second sample was 66 months. None of the 37 patients had any thrombotic event and 24 had a reactional state and were still requiring the use of prednisone, thalidomide or both. None of them fulfilled World Health Organization criteria for leprosy recurrence.</abstract><doi>10.1177/0961203314529469</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 2014-10, Vol.23 (12), p.1249-1251
issn 0961-2033
language eng
recordid cdi_proquest_miscellaneous_1683348715
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)
title Long-term persistence of anti- beta 2 glycoprotein I in treated leprosy patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A03%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20persistence%20of%20anti-%20beta%202%20glycoprotein%20I%20in%20treated%20leprosy%20patients&rft.jtitle=Lupus&rft.au=Ribeiro,%20SLE&rft.date=2014-10-01&rft.volume=23&rft.issue=12&rft.spage=1249&rft.epage=1251&rft.pages=1249-1251&rft.issn=0961-2033&rft_id=info:doi/10.1177/0961203314529469&rft_dat=%3Cproquest%3E1683348715%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p118t-5be9f7a0471e6c28af1767fa5eadbdecb24b2c6ddb047f10b69663777f6dee393%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1683348715&rft_id=info:pmid/&rfr_iscdi=true